How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• On modern GLP‑1/GIP drugs many people lose meaningful weight fairly quickly — often noticeable in the first 8–12 weeks — and average much larger losses over 6–18 months than with diet/exercise alone.
• Typical trial results: semaglutide (Wegovy) produced ~15% average body‑weight loss at ~68 weeks; tirzepatide (Zepbound/Mounjaro data) produced larger losses (up to ~20%+ at ~72 weeks) in clinical trials.
• Sustainability: benefits are usually maintained only while the drug is continued and paired with ongoing lifestyle changes and medical follow‑up. Stopping therapy commonly leads to partial or full weight regain.

How fast — more detail

• Early phase (first 1–3 months): many people lose a few percent of body weight quickly because appetite drops and food intake falls. It’s common to see 3–7% loss in the first 12–16 weeks for full therapeutic doses.
• Medium/long term (6–18 months): in randomized trials on approved doses:
  • Semaglutide 2.4 mg weekly (Wegovy): ~15% average weight loss at ~68 weeks (STEP trials).
  • Tirzepatide at higher doses (SURMOUNT trials; marketed as Zepbound for weight management and Mounjaro for diabetes): average losses in the 17–22% range at ~72 weeks at the highest doses in trials.
• Individual results vary widely: some people lose less, others more. Baseline weight, dose, adherence, diet, exercise, metabolism, and other medications all affect rate.

Why pace varies

• Dose: higher, approved obesity doses produce larger weight loss than lower diabetes doses.
• Behavior: structured diet, activity, and behavioral counseling magnify results.
• Biology: genetics, hormones, sleep, mental health, and other meds matter.
• Side effects: nausea or GI upset early on can reduce calorie intake (and weight) temporarily.

Is the weight loss sustainable?

• GLP‑1/GIP drugs are effective tools but usually not a permanent “cure.” Trials and real‑world follow‑ups show:
  • Continuing medication + lifestyle support = maintained or further loss.
  • Stopping medication often causes weight regain over months to years back toward baseline unless strong lifestyle/behavior changes are in place.
• Many clinicians treat obesity like other chronic conditions (hypertension, diabetes): ongoing medication may be needed for long‑term control.

Safety and who should be careful

• Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite — usually worst during dose escalation.
• Important cautions: personal/family history of medullary thyroid carcinoma or MEN2, pregnancy/planning pregnancy, history of pancreatitis — discuss with your clinician. Regular follow‑up is important for labs and monitoring side effects.

Practical next steps and brand/service suggestions

• Medications to discuss with a clinician:
  • Wegovy (semaglutide 2.4 mg weekly) — FDA‑approved for chronic weight management; robust trial data.
  • Zepbound (tirzepatide) — FDA‑approved for weight management; tends to produce larger losses in trials.
  • Mounjaro (tirzepatide) and Ozempic (semaglutide) — approved for diabetes but often discussed/off‑label for weight; dosing and approval differ. Rybelsus = oral semaglutide (less effective for weight than injectable high‑dose semaglutide).
• Who to see:
  • Start with your primary care doctor or an obesity medicine specialist. Use the American Board of Obesity Medicine (ABOM) directory to find certified specialists or check your local academic medical center’s obesity/metabolic clinic.
  • If telemedicine is more convenient, choose reputable, physician‑led services that offer medical evaluation, labs, and follow‑up rather than direct‑to‑consumer “prescription without assessment” outfits.
• Plan: medically evaluate, set realistic targets (e.g., 5–15% first year is common), start at the recommended dose escalation schedule, combine with nutrition/behavior counseling, and plan long‑term follow‑up.

If you want, tell me:

• your approximate current weight/height, whether you have diabetes or other medical conditions, and whether you’re interested in Wegovy vs. tirzepatide — I can help estimate likely percent loss ranges and outline a monitoring plan you can discuss with your clinician.